

## **Innovative Biosensors, Inc. to Present at Acumen Rodman & Renshaw Conference**

ROCKVILLE, MD, May 10, 2007 – Innovative Biosensors, Inc. (IBI), a company developing rapid, ultra-sensitive tests to detect harmful pathogens for both the clinical and biodefense markets, today announced that Joe Hernandez, President and Chief Executive Officer, has been invited to present at the Acumen BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference on May 14, 2007. The conference will take place in Monte Carlo, Monaco.

“We are delighted to be part of such a prestigious healthcare focused meeting and are excited to be proactively communicating our progress and business strategy to potential partners and investors at events such the Rodman & Renshaw conference,” said Joe Hernandez, President and CEO of IBI.

### **About Innovative Biosensors, Inc.**

Innovative Biosensors, Inc. is a privately held company developing novel technologies for the rapid detection of pathogens in biodefense applications and human clinical diagnostics. IBI's technology has been tailored to rapidly and sensitively detect biological threats in building security, military, and civil defense applications. Additionally, the technology platform is being used to develop rapid tests for the detection of hospital-acquired infections. Additional information is available at [www.innovativebiosensors.com](http://www.innovativebiosensors.com).

###

*This release may contain forward-looking statements that are subject to certain risks and uncertainties, including Innovative Biosensors, Inc.'s mission to develop and commercialize instrument systems, Innovative Biosensors, Inc.'s ability to develop new technologies to conduct rapid diagnosis. Such statements are based on management's current expectations and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Innovative Biosensors, Inc. cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including, but not limited to, the following: Innovative Biosensors, Inc.'s expectations that they will incur operating losses in the near future, the early stage of preclinical and clinical testing and trials, uncertainties surrounding the availability of additional funding, Innovative Biosensors, Inc.'s reliance on research collaborations, the actions of competitors and the development of competing technologies, potential patent infringement claims against Innovative Biosensors, Inc.'s products, processes and technologies, Innovative Biosensors, Inc.'s ability to protect their patents and proprietary rights and uncertainties relating to commercialization rights.*

#### **Contact:**

Joe Hernandez  
President and CEO  
Innovative Biosensors, Inc.  
Phone: 301.517.0324  
[www.innovativebiosensors.com](http://www.innovativebiosensors.com)  
[info@innovativebiosensors.com](mailto:info@innovativebiosensors.com)